BBHC
BHVN

Brown Brothers Harriman & Co’s Biohaven Pharmaceutical Holding Company Ltd. BHVN Stock Holding History

Brown Brothers Harriman & Co’s Portfolio BHVN Stock Details BHVN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-159
Closed -$24K – 1585
2022
Q3 		$24K Buy
+159
New +$23.6K ﹤0.01% 935

Other funds holding BHVN

LIP
Liontrust Investment Partners London, United Kingdom $5.86B AUM 23.75% 1-Year Est. Return
KCM
Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return
BC
Birchview Capital Burlington, Vermont $176M AUM 95.04% 1-Year Est. Return
BTI
Blue Trust Inc Alpharetta, Georgia $9.54B AUM 19.86% 1-Year Est. Return
FIA
FNY Investment Advisers New York $278M AUM 98.99% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
MSCM
McElhenny Sheffield Capital Management Dallas, Texas $404M AUM 19.8% 1-Year Est. Return

Brown Brothers Harriman & Co's BHVN Position: Q4 2022 in Review

Brown Brothers Harriman & Co sold out of Biohaven Pharmaceutical Holding Company Ltd. (BHVN) in Q4 2022, closing a stake of 159 shares — an estimated $24K sold.

Brown Brothers Harriman & Co first reported a position in BHVN in Q3 2022 and held it in 1 quarter. The position peaked at $24K in Q3 2022. 7 funds tracked by Wall St. Rank hold BHVN as of Q4 2022.

  • Brown Brothers Harriman & Co reported no remaining Biohaven Pharmaceutical Holding Company Ltd. position as of Q4 2022 after selling out during the quarter.
  • Brown Brothers Harriman & Co sold 159 Biohaven Pharmaceutical Holding Company Ltd. shares in Q4 2022, an estimated $24K.
  • Brown Brothers Harriman & Co first reported a position in Biohaven Pharmaceutical Holding Company Ltd. in Q3 2022 and held it in 1 quarter.
  • Brown Brothers Harriman & Co's Biohaven Pharmaceutical Holding Company Ltd. position peaked at $24K in Q3 2022.
  • 7 funds tracked by Wall St. Rank held Biohaven Pharmaceutical Holding Company Ltd. as of Q4 2022.

Based on Brown Brothers Harriman & Co's 13F filing for Q4 2022, filed 9 Feb 2023.